Introduction  by Marie, Jean-Pierre
International Journal of Infectious Diseases (2006) 10(S2) S1–S2
Introduction
Jean-Pierre Marie
Department of Haematology-Medical Oncology, Hoˆpital Hotel Dieu, Paris, France
Summary In this symposium entitled The Management of Neutropenic Patients with Fever Undergoing Chemotherapy
for the Treatment of Haematological Malignancies held during the 16th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) 2006, the current trends in bacterial resistance, the available data on the treatment of fever
and the best possible usage of antibiotics in neutropenic patients were reviewed.
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In patients with cancer, infections are a serious com-
plication because of the high mortality and morbidity
associated with these episodes 1,2. In patients treated
with chemotherapy, the risk of infection depends on the
duration and intensity of the neutropenia. Management
of these episodes has undergone a number of revisions
in the past two decades. Experience has taught us that
empirical treatment should be initiated as quickly as
possible 3. Antibiotic therapy should be tailored to the
local epidemiology, including the expected pathogens and
local resistance patterns. Treatment should also be risk-
adapted 4,5. Patients who are considered low risk, that
is patients with a single oral temperature of >38.3ºC or
>38.0ºC over at least one hour and a neutrophil count
between 1 and 0.5×109/l with an expected duration
of no more than 10 days post-chemotherapy, may be
treated with oral antibiotics. In high-risk patients, that
is those with a neutrophil count <500 cells/ml, prolonged
or profound neutropenia following chemotherapy or
hematopoietic stem cell transplant (HSCT) recipients,
empirical intravenous antibiotics should be initiated.
Surveillance data shows that there are important
differences both in the aetiology of infection and in
the susceptibility of organisms to antibiotics. At this
symposium, data from the European Organisation for
Research and Treatment of Cancer (EORTC) was presented
showing a shift in single organism bacteraemias from Gram-
negative organisms in the 1970s–1980s to Gram-positives
from the mid-1980s 6-10. More recently, the Gram-negatives
are re-emerging as the predominant pathogens in Europe,
whereas in the USA the Gram-positives still predominate.
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A number of reasons (see the paper by Arkova, p. S3) have
been attributed to these regional differences and changes,
including the use of central venous catheters and antibiotic
prophylaxis with the ﬂuoroquinolones.
Improvements in therapy and supportive care have been
accompanied by a gradual improvement in survival rates
for neutropenic patients 11. Antibiotic treatment options,
guidelines and a recommendation for treatment guidelines
are discussed in this supplement in depth by Glasmacher
(p. S9). In Bonn the recommendations for empirical therapy
in low-risk patients are for oral combination therapy
(amoxicillin–clavulanic acid plus ﬂuoroquinolone), and in
high-risk patients (or those unsuitable for oral therapy)
monotherapy with piperacillin/tazobactam, meropenem or
imipenem or a combination of a b-lactam antibiotic with
an aminoglycoside.
The ﬁnal paper in the supplement (Weber, p. S17)
discusses the need to balance prudent antibiotic use
and stewardship with effective patient management. The
safety proﬁle of an antibiotic is an additional consideration
when considering the choice of therapy 12. The need to
avoid collateral damage [such as Clostridium difﬁcile-
associated diarrhoea (CDAD)] and optimising the use of
antimicrobials must inform the therapeutic choice of
agent 13. Other therapeutic challenges include a changing
population of patients with increased severity of illness and
increasing numbers of immunocompromised patients 12,14.
Resistance to antibiotics is associated with use, is
progressive and organisms resistant to one agent are
likely to become resistant to other antibiotics. Clinicians
need to be aware that use of these agents affects
others in both the immediate and extended environment.
The appropriate use of antibiotics and infection control
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measures are important interventions in controlling the
spread of resistant pathogens.
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